

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patent Owner.

Case IPR2018-01427
U.S. Patent No. 8,597,649

**TEVA PHARMACEUTICALS INTERNATIONAL GMBH'S
EXHIBIT LIST**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Exhibit #	Description
2001	Edvinsson, L., "Calcitonin Gene-Related Peptide (CGRP) in Cerebrovascular Disease," <i>TheScientificWorldJOURNAL</i> , 2:1484–90 (2002)
2002	Hasbak, P., <i>et al.</i> , "Investigation of CGRP Receptors and Peptide Pharmacology in Human Coronary Arteries. Characterization with a Nonpeptide Antagonist," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 304:326–33 (2003)
2003	Brain, S. and Grant, A., "Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin," <i>Physiol Rev.</i> , 84:903-34 (2004)
2004	Chiba, T., <i>et al.</i> , "Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37)," <i>Am. J. Physiol.:Endocrin. & Metab.</i> , 19:E331-35 (1989)
2005	File History for U.S. Patent No. 8,597,649 B2
2006	Gegg, Jr., C., <i>et al.</i> , "CGRP Peptide Antagonists And Conjugates," U.S. Patent No. 8,168,592 B2 (filed October 19, 2006; issued May 1, 2012)
2007	Escott, K. and Brain, S., "Effect of a calcitonin gene-related peptide antagonist (CGRP ₈₋₃₇) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve," <i>Br. J. Pharmacol.</i> 110:772-76 (1993)
2008	Rist, B., <i>et al.</i> , "CGRP 27-37 analogues with high affinity to the CGRP ₁ receptor show antagonistic properties in a rat blood flow assay," <i>Regul. Pept.</i> 79:153-58 (1999)
2009	Edvinsson, L., "Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache," <i>Cephalalgia</i> , 24:611-22 (2004)
2010	Goadsby, P., "Calcitonin Gene-Related Peptide Antagonists as Treatments of Migraine and Other Primary Headaches," <i>Drugs</i> , 65:2557-67 (2005)
2011	Supowit, S., <i>et al.</i> , "Calcitonin Gene-Related Peptide Protects Against Hypertension-Induced Heart and Kidney Damage," <i>Hypertension</i> , 45:109-14 (2005)

Exhibit #	Description
2012	Aiyar, N., <i>et al.</i> , “Pharmacology of SB-273779, a Nonpeptide Calcitonin Gene-Related Peptide 1 Receptor Antagonist,” <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 296:768–75 (2001)
2013	Rudolf, K., <i>et al.</i> , “Modified Aminoacids, Pharmaceuticals Containing These Compounds and Method for Their Production,” U.S. Patent Application Publication No. 2003/0069231 A1 (filed April 10, 2002; published April 10, 2003)
2014	Patchett, A., <i>et al.</i> , “Benzimidazoliny Piperidines as CGRP Ligands,” U.S. Patent No. 6,552,043 B1 (filed September 22, 1999; issued April 22, 2003)
2015	Zimmer, O., <i>et al.</i> , “Substituted Cyclopentene Compounds,” U.S. Patent No. 7,109,214 B2 (filed November 19, 2004; issued September 19, 2006)
2016	Chaturvedula, P., <i>et al.</i> , “Constrained Compounds as CGRP-Receptor Antagonists,” U.S. Patent No. 7,384,930 B2 (filed October 11, 2005; issued June 10, 2008)
2017	Rudolf, K., <i>et al.</i> , “Modified Aminoacids, Pharmaceuticals Containing These Compounds and Method for Their Production,” U.S. Patent No. 6,344,449 B1 (filed September 8, 1997; issued February 5, 2002)
2018	Paone, D., <i>et al.</i> , “CGRP Receptor Antagonists,” U.S. Patent No. 7,772,224 B2 (filed April 3, 2009; issued August 10, 2010)
2019	Petersen, K., <i>et al.</i> , “The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers,” <i>Cephalalgia</i> , 25:139–47 (2004)
2020	Leahy, D., <i>et al.</i> , “Process For The Preparation of Cycloheptapyridine CGRP Receptor Antagonists,” U.S. Patent No. 8,669,368 B2 (filed September 19, 2011; issued March 11, 2014)
2021	Clinical Trials for BIBN4096BS, downloaded from https://clinicaltrials.gov/ct2/results?cond=&term=bibn4096bs&cntry=&state=&city=&dist (last accessed November 5, 2018)

Exhibit #	Description
2022	Clinical Trials for MK-0974, downloaded from https://clinicaltrials.gov/ct2/results?cond=&term=mk-0974&cntry=&state=&city=&dist (last accessed on November 15, 2018)
2023	Clinical Trials for BMS-927711, downloaded from https://clinicaltrials.gov/ct2/results?cond=&term=BMS-927711&cntry=&state=&city=&dist (last accessed on November 5, 2018)
2024	Zeller, J., <i>et al.</i> , “Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same,” U.S. Patent No. 8,007,794 B2 (filed November 2, 2006; issued August 30, 2011)
2025	Zeller, J., <i>et al.</i> , “Methods of Using Anti-CGRP Antagonist Antibodies,” U.S. Patent No. 8,586,045 B2 (filed July 11, 2011; issued November 19, 2013)
2026	Zeller, J., <i>et al.</i> , “Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same,” U.S. Patent No. 9,340,614 B2 (filed August 31, 2015; issued May 17, 2016)
2027	Zeller, J., <i>et al.</i> , “Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same,” U.S. Patent No. 9,266,951 B2 (filed August 31, 2015; issued February 23, 2016)
2028	Zeller, J., <i>et al.</i> , “Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same,” U.S. Patent No. 9,346,881 B2 (filed August 31, 2015; issued May 24, 2016)
2029	Zeller, J., <i>et al.</i> , “Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide,” U.S. Patent No. 9,890,210 B2 (filed May 5, 2017; issued February 13, 2018)
2030	Zeller, J., <i>et al.</i> , “Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide,” U.S. Patent No. 9,890,211 B2 (filed May 5, 2017; issued February 13, 2018)
2031	Zeller, J., <i>et al.</i> , “Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide,” U.S. Patent No. 9,884,907 B2 (filed May 5, 2017; issued February 6, 2018)
2032	Zeller, J., <i>et al.</i> , “Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide,” U.S. Patent No. 9,884,908 B2 (filed May 5, 2017; issued February 6, 2018)
2033	File History for U.S. Patent No. 8,007,794 B2

Case IPR2018-01427

Patent No. 8,597,649

<i>Exhibit #</i>	<i>Description</i>
2034	File History for U.S. Patent No. 8,586,045 B2
2035	File History for U.S. Patent No. 8,734,802 B1
2036	File History for U.S. Patent No. 9,115,194 B2
2037	File History for U.S. Patent No. 9,328,168 B2
2038	File History for U.S. Patent No. 9,346,881 B2
2039	File History for U.S. Patent No. 9,266,951 B2
2040	File History for U.S. Patent No. 9,340,614 B2
2041	File History for U.S. Patent No. 9,365,648 B1
2042	File History for U.S. Patent No. 9,890,211 B2
2043	File History for U.S. Patent No. 9,890,210 B2
2044	File History for U.S. Patent No. 9,884,907 B2
2045	File History for U.S. Patent No. 9,884,908 B2
2046	Clinical Trials for BHV-3000, downloaded from https://clinicaltrials.gov/ct2/results?cond=&term=bhv-3000&cntry=&state=&city=&dist (last accessed on November 5, 2018)
2047	Alberts, B., <i>et al.</i> , <i>Molecular Biology of the Cell</i> , p. G:34, 4 th ed., Garland Science, Taylor & Francis Group, New York (2002)
2048	John H. Byrne, <i>Essential Medical Physiology, Chapter 6: Neuromuscular and Synaptic Transmission</i> , pp. 97-122, (Leonard R. Johnson, ed.), 3 rd Ed., Elsevier Academic Press, Amsterdam (2003)
2051	<i>Intentionally left blank</i>
2052	Inman, S., "Anti-CGRP Monoclonal Antibodies Transforming Migraine Treatment," (Oct. 22, 2018), <i>NeurologyLive</i> https://www.neurologylive.com/conferences/ana-2018/anticgrp-monoclonal-antibodies-transforming-migraine-treatment , (last visited May 20, 2019)
2053	"Pain Like No Other," <i>UCLA Health David Geffen School of Medicine</i> 38(2): 18-25 (2018)
2054	Declaration of Steven M. Foord, Ph.D.
2055	Curriculum Vitae of Steven M. Foord, Ph.D.
2056	Hay, D.L., <i>et al.</i> , "A comparison of the actions of BIBN4096BS and CGRP ₈₋₃₇ on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells," <i>British Journal of Pharmacology</i> 137(1): 80 - 86 (2002)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.